Online inquiry

IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ802MR)

This product GTTS-WQ802MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ802MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11062MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ12005MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ97MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ11144MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ2725MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ12447MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ14400MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ8028MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW